Comparative in vivo studies with paclitaxel and liposome-encapsulated paclitaxel

International Journal of Oncology

Volumn 12, Issue 5, 1998, Pages 1035-1040

  Cabanes, Ana ^a   Briggs, Kerrie E ^a   Gokhale, Prafulla C ^a   Treat, Joseph A ^b   Rahman, Aquilur ^a,c  

^a GEORGETOWN UNIVERSITY MEDICAL CENTER   (United States)

^b HOSPITAL OF THE UNIVERSITY OF PENNSYLVANIA   (United States)

^c NeoPharm Inc   (United States)

Author keywords

In vivo; Liposomes; Paclitaxel

Indexed keywords

LIPOSOME; PACLITAXEL;

ANIMAL CELL; ANTINEOPLASTIC ACTIVITY; AREA UNDER THE CURVE; ARTICLE; DOSE TIME EFFECT RELATION; DRUG EFFICACY; DRUG FORMULATION; IN VIVO STUDY; MICROTUBULE ASSEMBLY; MOUSE; NONHUMAN; PRIORITY JOURNAL; TISSUE DISTRIBUTION;

EID: 0031955507     PISSN: 10196439     EISSN: None     Source Type: Journal    
DOI: 10.3892/ijo.12.5.1035     Document Type: Article

References (21)

1. Rowinsky EK and Donehower RC: Paclitaxel (Taxol). N Engl J Med 332: 1004-1014, 1995.
2. Lorenz W, Riemann HJ, Schmal A, Schult H, Lang S, Ohmann C, Weber D, Kapp B, Luben L and Doenicke A: Histamine release in dogs by Chremophor EL and its derivatives: oxyethylated oleic acid is the most effective constituent. Agents Actions 7: 63-67, 1977.
3. Weiss RB, Donehover RC, Wiernik PH, Ohnuma T, Gralla RJ, Trump DL, Baker JR Jr, van Echo DA, von Hoff DD and Leyland-Jones B: Hypersensitivity reactions from taxol. J Clin Oncol 8: 1263-1268, 1990.
4. Schiller JH, Storer B, Tutsch K, Arzoomanian R, Alberti D, Feierabend C and Spriggs D: Phase I trial of 3 hour infusion of paclitaxel with or without granulocyte colony-stimulating factor in patients with advanced cancer. J Clin Oncol 12: 241-248, 1994.
5. Hurwitz CA, Relling MV, Weitman SD, Ravindranath Y, Vietti TJ, Strother DR, Ragab AH and Pratt CB: Phase I trial of paclitaxel in children with refractory solid tumors: a Pediatric Oncology Group study. J Clin Oncol 11: 2324-2329, 1994.
6. Sonnichsen DS, Hurwitz CA, Pratt CB, Shuster JJ and Relling MV: Saturable pharmacokinetics and paclitaxel pharmacodynamics in children with solid tumors. J Clin Oncol 12: 532-538, 1994.
7. Gianni L, Kearns CM, Capri G, Vigano L, Locatelli A, Bonadonna G, Giani A and Egorin MJ: Nonlinear pharmacokinetics and metabolism of paclitaxel and its pharmacokinetic/pharmacodynamic relationships in humans. J Clin Oncol 13: 180-190, 1995.
8. Sparreboom A, van Tellingen O, Nooijen WJ and Beijnen JH: Nonlinear pharmacokinetics of paclitaxel in mice results from the pharmaceutical vehicle Chemophor EL. Cancer Res 56: 2112-2115, 1996.
9. Gabizon A, Dagan A, Goren D, Barenholz Y and Fuks Z: Liposomes as in vivo carriers of Adryamycin: reduced cardiac uptake and preserved anti-tumor activity in mice. Cancer Res 42: 4734-4739, 1982.
10. Mayhew E and Papahadjopoulos D: Therapeutic applications of liposomes. In: Liposomes. Ostro MJ (ed). Marcel Dekker, New York, pp289-341, 1983.
11. Gokhale PC, Radhakrishnan B, Husain SR, Abernethy DR, Sacher R, Dritschilo A and Rahman A: An improved method of encapsulation of doxorubicin in liposomes: pharmacological, toxicological and therapeutic evaluation. Br J Cancer 74: 43-48, 1996.
12. Rahman A, Husain RS, Siddiqui J, Verma M, Agresti M, Center M, Safa AR and Glazer RI: Liposome-mediated modulation of multidrug resistance in human HL-60 leukaemia cells. J Natl Cancer Inst 84: 1909-1915, 1992.
13. Thierry AR, Vige D, Coughlin SS, Belli JA, Dritschilo A and Rahman A: Modulation of doxorubicin resistance in multidrug-resistant cells by liposomes. FASEB J 7: 572-579, 1993.
14. Gibaldi M and Perrier D: Pharmacokinetics. Marcel Dekker, New York, 1982.
15. Huizing MT, Sewberath Misser VH, Pieters RC, Ten Bokkel Huinink WW, Veenhof CHN, Vermorken JB, Pinedo HM and Beijnen JH: Taxanes. A new class of antitumor agents. Cancer Invest 13: 381-404, 1995.
16. Kris MG, O'Connell JP, Gralla RJ, Wertheim MS, Parente RM, Schiff PB and Young CW: Phase I trial of taxol given as a 3-hour infusion every 21 days. Cancer Treat Rep 70: 605-607, 1986.
17. Popescu MC, Swenson CE and Ginsberg RS: Liposome-mediated treatment of viral, bacterial, and protozoal infections. In: Liposomes: from Biophysics to Therapeutics. Ostro MJ (ed). Marcel Dekker, New York, pp219-251, 1987.
18. Gregoriadis G and Florence AT: Liposomes in drug delivery: clinical, diagnostic and ophthalmic potential. Drugs 45: 15-28, 1993.
19. Rahman A, Treat J, Roe JK, Potkul LA, Gregory Alvord W, Forst D and Woolley PV: A phase I clinical trial and pharmacokinetic evaluation of liposome-encapsulated doxorubicin. J Clin Oncol 8: 1093-1100, 1990.
20. Sharma A, Mayhew E and Straubinger M: Antitumor effect of taxol-containing liposomes in taxol-resistant murine tumor model. Cancer Res 53: 5877-5881, 1993.
21. Sharma A, Mayhew E, Bolcsak L, Cavanaugh C, Harmon P, Janoff A and Bernacki RJ: Activity of paclitaxel liposome formulations against human ovarian tumor xenografts. Int J Cancer 71: 103-107, 1997.